Molbio Diagnostics Limited

Minimum Investments

₹13,824

Price Range

₹768 - ₹807

Issue Size

₹939.70 Cr

Lot Size

18shares

Proceeds of this IPO to be used for

Funding capital expenditure towards the setting up of infrastructure for the research and development facility, Centre of Excellence and connected office space

Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for the Goa & Visakhapatnam Units

General corporate purposes

Strengths & Weaknesses

Innovative and R&D focused

The company has strong in-house R&D through its subsidiary Bigtec, with a proven record of developing innovative POC diagnostic platforms. Its 13+ years of research led to ICMR-certified solutions, including one of the earliest POC PCR platforms for influenza and swine flu diagnosis

Truenat platform

The company has developed and commercialised ‘Truenat,’ a portable POC molecular diagnostics platform using PCR technology. It includes the Trueprep device for automated sample preparation, the Truelab analyser for real-time PCR, and ready-to-use Truenat test kits for disease-specific diagnostics

Scalable business model

The company’s ‘Truenat’ platform is a closed system of Trueprep and Truelab devices that work exclusively with its disease-specific test kits, ensuring recurring demand. With WHO endorsement for TB diagnosis and high entry barriers backed by 13 years of R&D, the platform enables testing for multiple diseases on the same device, enhancing value for healthcare providers

Complex & uncertain sales cycle

The company’s sales cycle is complex and variable, involving multiple stakeholders such as clinicians, pathologists, and laboratories. Dependence on clinician prescriptions, government orders, and lengthy approval processes often leads to delays and fluctuations in demand, making accurate sales forecasting challenging

Inventory risks

The company’s inability to accurately forecast demand or manage inventory can impact operations and finances. Unpredictable factors like disease outbreaks or sudden large orders may cause excess stock or shortages, leading to potential business loss

Product liability & regulatory risks

Product liability claims, regulatory actions, or penalties for failing contractual obligations may harm the company’s business, finances, and reputation. Such claims can be costly, time-consuming, and may result in substantial damages or loss of brand credibility

Financials

Income Statement

Also called a profit and loss statement, an income statement shows a company’s income, expenses, and how much profit or loss it has made over a specific accounting period. It provides a clear view of how well the business is running.

Particulars (in Cr)	Mar 2026	Y/Y Change
Operating Revenue	1,445.69	+41.68%
Other Income	9.48	+26.06%
Total Income	1,455.17	+41.56%
Total Expenditure	1,221.35	+48.87%
EBIDT	330.93	+22.68%
Depreciation	63.64	+42.85%
Interest	33.47	+89.52%
Tax	67.00	+19.96%
Net Profit	166.59	+14.81%

Balance Sheet

A balance sheet is a financial statement that details a company’s assets, liabilities, and shareholders’ equity at a given time. It helps assess how financially strong and stable the company is.

Particulars (in Cr)	Mar 2026
Total Current Assets	1,384.84
Total Non-Current Assets	763.58
Fixed assets	485.56
Total Assets	2,148.42
Total Current liabilities	557.36
Total Non Current Liabilities	282.29
Total Equity Plus Liabilities	2,148.42
Total Shareholder Funds	1,169.34
Total Debt to Equity	35.00%

Cash Flow

Cash flow highlights the cash or cash equivalents moving in and out of a company during a particular period. It provides a clear picture of how well a company manages its cash by tracking its operating, investing and financing activities.

Particulars (in Cr)	Mar 2026
Cash from Operating Activity	50.38
Cash from Financing Activities	276.07
Cash from Investing Activities	-93.22
Net Cash Flow	233.23

About the Company

Molbio Diagnostics was incorporated on October 20, 2000. The company develops innovative point-of-care diagnostics through its patented ‘Truenat’ PCR platform, enabling rapid testing for 30+ diseases across 100+ countries. It also offers radiology, digital pathology, and breast health solutions while building a pipeline of new products

Promoter
Sriram Natarajan
Promoter
Chandrasekhar Bhaskaran Nair
Promoter
Sangeetha Sriram
Promoter
Shiva Sriram
Promoter
Sowmya Sriram
Promoter
Exxora Trading LLP

FAQs for Molbio Diagnostics Limited IPO

Molbio Diagnostics Limited IPO refers to the initial public offering of shares by Molbio Diagnostics Limited. It is a process by which the company offers its shares to the public for the first time, allowing individuals to become shareholders.

For Molbio Diagnostics Limited IPO the issue size is ₹940 Cr. The issue size is the total value of the shares offered to the public. It represents the amount the company aims to raise through the IPO.

For Molbio Diagnostics Limited IPO the minimum investment is ₹13.8 K. The minimum investment for Molbio Diagnostics Limited IPO is the smallest amount an individual can invest to participate in the offering. It is usually determined by the company and regulatory requirements.

For Molbio Diagnostics Limited IPO the lot size is 18 shares. The lot size of Molbio Diagnostics Limited IPO refers to the number of shares that investors need to bid for and purchase in a single transaction. It is predetermined by the company and regulators.

To apply for Molbio Diagnostics Limited IPO on Share.Market, go to the home page section and click/press on the browse IPOs section to view the open and upcoming IPOs. Select the Molbio Diagnostics Limited IPO from the list and click on apply now. Place your bids or choose the Cut-off Price option. Enter your UPI ID and set up your mandate to place your application.

Yes, investors can often pre-apply for some of the IPOs. Pre-application allows individuals to express their interest in participating in the IPO before the official subscription period begins. To pre- apply for Molbio Diagnostics Limited IPO on Share.Market, go to the home page section and click/press on the browse IPOs section to view the open and upcoming IPOs. Select the Molbio Diagnostics Limited IPO from the list and click on pre-apply now. Once the IPO opens for subscription you can enter your UPI ID and set up your mandate to place your application.

The IPO application window typically remains open for 3 days, starting from the date of the IPO opening. However, this duration can vary depending on the specific IPO and the regulatory requirements.

You can apply for the IPO till 3 PM on the last day of application on Share.Market.

For Molbio Diagnostics Limited IPO the allotment date is 13 Aug 2026. The allotment date of Molbio Diagnostics Limited IPO is the date on which shares are allocated to the successful bidders. It marks the distribution of shares to investors.

For Molbio Diagnostics Limited IPO, the subscription opens on 10 Aug 2026 and closes on 12 Aug 2026. The open and close dates of an IPO indicate the period during which investors can submit their bids to participate in the offering.